Classification of adverse reproductive effects can be improved by measurements of multiple biomarkers for ovarian toxicity and early fetal loss.
Lasley-BL; Gold-EB; Nakajima-ST; Stewart-DR; Overstreet-JW
J Toxicol Environ Health 1993 Oct-Nov; 40(2-3):423-433
The application of biomarkers in the assessment of reproductive function in exposed populations was considered. Daily early morning urine samples can be used to assess early pregnancy loss, menstrual dysfunction, reduced fertility, and the site of reproductive toxicity. Measurements of human chorionic gonadotropin together with measurements of metabolites of ovarian steroids and peptides could be used to evaluate early fetal loss. The metabolites of the pituitary gonadotropins, luteinizing hormone and follicle stimulating hormone, together with those of ovarian steroids and peptides, may be used to evaluate fertility and menstrual/ovarian function. Measurements of these hormones provide direct information on the functional integrity of their tissue source, and may provide additional information concerning the health of their target organs. Conventional clinical concepts for detection of reproductive organ toxicity, which are based on the understanding of the feedback mechanisms in the hypothalamic pituitary ovarian axis, will be applied in population based studies of the future. The authors conclude that the continuing advances in reproductive endocrinology hold the promise of providing a wider range of more specific reproductive biomarkers that are based not only on traditional immunoassays of individual hormones, but also on our knowledge of hormone to hormone interactions.
Biological-monitoring; Risk-analysis; Endocrine-system; Epidemiology; Metabolic-study; Reproductive-system-disorders; Urinalysis; Reproductive-hazards; Hormone-activity
Journal of Toxicology and Environmental Health
CA; MN; DE; KS; MD; NJ; VA; WA
University of California - Davis